Clinical Trials Browser

Phase 2 × avelumab × Breast × Clear all

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 2 Active not recruiting

100 enrolled 15 charts

Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2 Active not recruiting

48 enrolled 13 charts

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03794596 2019-07-22

IMpALA

Phase 2 Withdrawn

Breast Neoplasms